NCT03968848View on ClinicalTrials.gov

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

March 13, 2019

Study Completion Date

March 29, 2019

Conditions
Hepatic ImpairmentHepatic InsufficiencyHealthy Subjects
Interventions
DRUG

acalabrutinib

A 50-mg single oral dose of acalabrutinib will be administered.

Trial Locations (3)

32809

Research Site, Orlando

33136

Research Site, Miami

37920

Research Site, Knoxville

Sponsors

Lead Sponsor

Acerta Pharma BV

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY